Last checked at 
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".
O'Brien will be succeeded by interim CFO Yrjö Wichmann on 15 April, who previously served as the firm's finance head from 2014 to 2019.
"As a former CFO of this company and, most recently, our Senior Vice President, Financing & IR, Yrjö is well positioned to take up the role of Interim CFO whilst we look for a permanent replacement." said chief executive, Markku Jalkanen.
"On behalf of the board, I would like to thank Jim for his service to Faron. His contributions, during very challenging market conditions, have been considerable and very much appreciated, and we wish him all the best in his next role."
As of 0935 BST, Faron shares were down 3.0% at 123.67p.
Reporting by Iain Gilbert at Sharecast.com
